SBI-115 - TGR5 (GPCR19) Antagonist - 生命科学试剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESBI-115Cat. No.: HY-111534CAS No.: 882366-16-7分式: CHClNOS分量: 340.78作靶点: GPCR19作通路: GPCR/G Protein储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 150 mg/mL (440.17 mM; Need ultrasonic)H2O :

2、40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (7.34 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (7.34 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 SBI-115种 TGR5 (GPCR19) 拮抗剂。SBI-115 通过抑制 TGR5 降低多囊性肝病的肝囊肿形成 1。体外研究

3、SBI-115 (100-200 M, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes withTaurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes 1.Cell Proliferation Assay 1Cell Line: shRNA-transfected ADPKD cholangiocytesConcentration: 100, 200 MIncubation Time: 2

4、4 hoursResult: Inhibited proliferation (by 32-48%) triggered by pre-treatment of cystic cholangiocyteswith TLCA.REFERENCES1. Masyuk TV, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosinemonophosphate/Gs signaling. Hepatology. 2017 Oct; 66(4):1197-1218.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;Fax: